Navigation Links
Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
Date:12/9/2013

SEATTLE, Dec. 10, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced promising interim results from an investigator-initiated Phase 2 clinical trial of tosedostat in combination with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. Tosedostat is administered orally and has been previously shown to induce complete remissions as monotherapy in relapsed or refractory AML. Researchers presented the findings from this combination study today for the first time at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition held December 7–10 in New Orleans, La.

"Treatment outcomes for older patients with newly diagnosed AML remain poor," said John Pagel, M.D., Ph.D., Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Associate Professor, Medical Oncology Division, University of Washington School of Medicine; and Principal Investigator in the tosedostat first-line AML/MDS trial. "This is the first time that tosedostat has been given in a front-line setting in combination with low intensity therapy. The complete response rates and median survival observed in previously untreated older patients with AML is promising and appears to be worthy of further clinical investigation." 

The Phase 2 trial was designed to test the efficacy of tosedostat in combination with low intensity therapy for older patients with previously untreated AML or high-risk MDS not considered candidates for standard intensive therapy. This presentation reported on the results of 26 patients (median age was 69) enrolled in t
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)...  The board of directors of AbbVie Inc. (NYSE: ... of $0.42 per share.  The cash ... record at the close of business on Oct. 15, ... research-based biopharmaceutical company formed in 2013 following separation from ... dedicated people and unique approach to innovation to develop ...
(Date:9/19/2014)... WHITEHOUSE STATION, N.J. , Sept. 19, 2014 Merck ... the United States and Canada , ... on Desafiando La Diabetes: Logra Tus Metas , an educational ... of their blood sugar -- a key treatment goal to help ... the United States are at a higher risk for ...
(Date:9/19/2014)... 19, 2014 Larry J. Merlo , President ... will speak before the National Press Club in ... recent move to stop selling tobacco products and its leadership ... health. "Dramatic changes in our health care system ... government," Merlo has said. "CVS Health has a truly unique ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
(Date:9/19/2014)... NH 9/18/14) A leading Dartmouth researcher, working with The ... a paper published today in the Journal of ... increase the risk of melanoma. , "For the first ... length of these telomeres play a part in the ... study Mark Iles, PhD, School of Medicine at the ...
(Date:9/19/2014)... September 19, 2014 According to a ... the embattled blood-thinner Xarelto, named as defendants in several ... Pleas, have moved the court to dismiss those suits ... have sufficient connection with Philadelphia.* The cases include, for ... (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), which was ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- U.S. military troops deployed ... skin cancer, according to a new study. ... researchers revealed. In some cases, military personnel developed blisters ... color, shape or size of their moles since being ... risk factors for skin cancer, the study authors noted. ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Pregnant women who live ... or low birth weight babies, a new study suggests. ... Canada, and found that expectant mothers who lived in a ... a 20 percent lower risk of very preterm birth (before ... preterm birth (30 to 36 weeks). Babies born to ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- The U.S. Food and ... on Thursday. Trulicity is part of a class of once-a-week ... with type 2 diabetes. "Trulicity is a new ... existing treatment regimens to control blood sugar levels in the ... director of the FDA,s Office of Drug Evaluation II, said ...
Breaking Medicine News(10 mins):Health News:Melanoma risk found to have genetic determinant 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... Susan Desmond-Hellmann, MD, MPH, will be inducted today ... alongside some of the world,s other most distinguished ... a renowned oncologist and biotechnology leader who now ... was among five members of the 210 new ...
... technique appears to offer quick and effective relief for ... cancer, researchers reported at the 35th Congress of the ... Many patients with multiple myeloma, or those whose cancer ... fractures in their spine. This is partly because the ...
... Diseases, part of the National Institutes of Health, has ... Virginia Bioinformatics Institute (VBI) and collaborators to determine how ... of the gut. The funding will be used to ... to gut pathogens. "The Center for Modeling Immunity ...
... HealthDay Reporter , FRIDAY, Oct. 8 (HealthDay News) -- Researchers ... may double the odds that a child will develop a ... The study authors aren,t calling for an end to childhood ... such as pneumonia and broken bones. And the study doesn,t ...
... treatment has shown encouraging activity as a first-line therapy ... Congress of the European Society for Medical Oncology (ESMO) ... MD, Mayo Clinic in Florida, presented the results of ... a first-line treatment for metastatic breast cancer. ...
... the European Health Award 2010 handed to the Chronic Disease ... 6 9 October 2010. The ESC was instrumental ... health professionals. The stepping stone was a policy conference organised ... together 10 European health organisations. In just a year, the ...
Cached Medicine News:Health News:UCSF Chancellor inducted into Academy of Arts and Sciences 2Health News:UCSF Chancellor inducted into Academy of Arts and Sciences 3Health News:Surgical technique relieves painful spine fractures in patients with metastatic cancer 2Health News:Virginia Bioinformatics Institute to model immune responses to gut pathogens 2Health News:Virginia Bioinformatics Institute to model immune responses to gut pathogens 3Health News:3 or More X-Rays May Raise Leukemia Risk Among Kids: Study 2Health News:3 or More X-Rays May Raise Leukemia Risk Among Kids: Study 3Health News:Targeted therapy promising for HER2-positive metastatic breast cancer 2Health News:Chronic Disease Alliance receives European Health Award 2010 2Health News:Chronic Disease Alliance receives European Health Award 2010 3Health News:Chronic Disease Alliance receives European Health Award 2010 4
Inquire...
... Used for the injection of contrast ... The dual lumen design eliminates the need ... designed to promote atraumatic passage into and ... layer of hydrophilic polymer that when activated, ...
Used for retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
Medicine Products: